Exemestane in the prevention setting-Reference-Cited by-同舟云学术

Exemestane in the prevention setting

Published:2012-02-22 Issue:3 Volume:4 Page:107-112
ISSN:1758-8359
Container-title:Therapeutic Advances in Medical Oncology
language:en
Short-container-title:Ther Adv Med Oncol

Author:

Litton Jennifer Keating¹,Bevers Therese B.²,Arun Banu K.³

Affiliation:

1. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA

2. Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

3. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Abstract

Aromatase inhibitors are well-established therapies in the neoadjuvant, adjuvant and metastatic settings for breast cancer. In adjuvant trials, this class of drugs has shown preventative properties by decreasing the rate of contralateral breast cancer. Recently, the National Cancer Institute of Canada Clinical Trials Group MAP.3 study evaluated exemestane as a breast cancer prevention agent for women with specified higher risks of developing breast cancer. We review the history of exemestane and evaluate the available evidence of its use for breast cancer prevention.

Publisher

SAGE Publications

Subject

Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1758834012438214

Reference35 articles.

1. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

2. A Qualitative Systematic Review of the Evidence Base for Non-cross-resistance between Steroidal and Non-steroidal Aromatase Inhibitors in Metastatic Breast Cancer

3. Aromatase inhibitors in ovarian stimulation

4. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study

5. Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence;Advances in Therapy;2022-01-06

2. Epidemiology, Risk Factors, and Prevention;Breast Disease;2019

3. Triggering of Suicidal Erythrocyte Death by Exemestane;Cellular Physiology and Biochemistry;2017

4. Unravelling exemestane: From biology to clinical prospects;The Journal of Steroid Biochemistry and Molecular Biology;2016-10

5. Epidemiology, Risk Factors, and Prevention;Breast Disease;2016